专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1988007054A1 COMPLEMENT-BINDING PEPTIDE 审中-公开
标题翻译：补充结合肽
公开(公告)号：WO1988007054A1
公开(公告)日：1988-09-22
申请号：PCT/GB1988000213
申请日：1988-03-18
申请人： RESEARCH CORPORATION LIMITED , WINTER, Gregory, Paul , DUNCAN, Alexander, Robert
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07K07/00
CPC分类号： C07K16/00
摘要： A polypeptide, having the ability to inhibit complement mediated lysis, consists of or contains the amino acid sequence (I): -X-A-Y-A-Z-, in which X is a polar amino acid, A is any amino acid; Y is a basic amino acid, and Z is a basic amino acid. In a preferred embodiment the polypeptide has the general formula (II): Head-X-A-Y-A-Z-Tail, in which X is Asn, Glu, Thr or Gln, Y and Z are, independently, Lys or Arg, 'Head' is a hydrogen atom or a sequence of amino acid residues attached to the amino group of the adjacent amino acid X, 'Tail' is a hydrogen atom or a sequence of amino acid residues attached to the carboxyl group of the adjacent amino acid Y, and, each of the groups represented by A, which may be the same or different, is an amino acid residue.
摘要翻译：具有抑制补体介导的裂解能力的多肽由X或A-Y-A-Z-组成或含有其中X为极性氨基酸的氨基酸序列（I），A为任何氨基酸; Y是碱性氨基酸，Z是碱性氨基酸。在优选的实施方案中，多肽具有通式（II）：头XAYAZ-尾，其中X是Asn，Glu，Thr或Gln，Y和Z独立地是Lys或Arg，'头'是氢原子或连接于相邻氨基酸X的氨基的氨基酸残基的序列，“尾”是与相邻氨基酸Y的羧基相连的氢原子或氨基酸残基的序列，由A表示的可以相同或不同的基团是氨基酸残基。

2. 发明申请

WO1989004834A1 IMMUNOGLOBULIN E COMPETITOR 审中-公开
标题翻译：免疫球蛋白E竞争者
公开(公告)号：WO1989004834A1
公开(公告)日：1989-06-01
申请号：PCT/GB1988001018
申请日：1988-11-18
申请人： RESEARCH CORPORATION LIMITED , GOULD, Hannah, Jane , HELM, Birgit, Anna , MARSH, Philip, John, Henry, Benedict
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07K07/00
CPC分类号： C07K16/00 , A61K38/00 , C07K16/4291
摘要： A polypeptide competitor or analogue for human Immunoglobulin E (IgE) low affinity sites comprises a polypeptide which has a sequence of amino acid which has a sequence of amino acids which is shown in Table I. This amino acid sequence corresponds to amino acids 340 to 439 of the epsilon heavy chain of IgE. A particularly preferred polypeptide competitor has a sequence of amino acids corresponding to amino acids 340 to 547 of the epsilon heavy chain of IgE as set out in Table V herein, which also shows the corresponding DNA sequence coding therefor. Such a polypeptide may also include additional short sequences at the beginning and/or end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to compete with native IgE for the low affinity receptor sites on human cells. The polypeptide may be produced synthetically or by expression from Escherichia coli containing a plasmid having a DNA segment coding for the polypeptide.
摘要翻译：用于人免疫球蛋白E（IgE）低亲和位点的多肽竞争剂或类似物包含具有氨基酸序列的多肽，其氨基酸序列如表I所示。该氨基酸序列对应于氨基酸340至439 的IgE重链。特别优选的多肽竞争剂具有对应于本文表V中列出的IgE的ε重链的氨基酸340至547的氨基酸序列，其也显示了编码的相应DNA序列。这样的多肽还可以在核心序列的起始和/或末端包括生理上无害的附加短序列，并且对核心序列与天然IgE与人细胞上的低亲和力受体位点竞争的能力没有贡献。多肽可以由含有编码多肽的DNA区段的质粒的大肠杆菌合成或表达产生。

3. 发明申请

WO1989008669A1 METHOD FOR PREPARING POLYMER BOUND STABILIZERS MADE FROM NON-HOMOPOLYMERIZABLE STABILIZERS 审中-公开
标题翻译：从非均聚稳定剂制备聚合物界限稳定剂的方法
公开(公告)号：WO1989008669A1
公开(公告)日：1989-09-21
申请号：PCT/GB1988000212
申请日：1988-03-18
申请人： RESEARCH CORPORATION LIMITED
发明人： RESEARCH CORPORATION LIMITED , SCOTT, Gerald , REKERS, John
IPC分类号： C08F08/00
CPC分类号： C08F8/00 , C08F8/30
摘要： A method of preparing a polymer bound stabilizer comprises reacting a stabilizer precursor molecule containing a reactive double bond which is not readily homopolymerizable with a preformed polymer in the presence of a free radical. The stabilizer precursor may be, for example, a hindered piperidine, a hindered phenol antioxidant or a hindered arylamine antioxidant and the polymer may be a polyolefin, polystyrene, polyvinyl chloride, polyamide or an acrylonitrile butadiene styrene polymer, for example.
摘要翻译：制备聚合物结合稳定剂的方法包括在自由基存在下使含有不能与预成型聚合物容易均聚的活性双键的稳定剂前体分子反应。稳定剂前体可以是例如受阻哌啶，受阻酚抗氧化剂或受阻芳胺抗氧化剂，并且聚合物可以是例如聚烯烃，聚苯乙烯，聚氯乙烯，聚酰胺或丙烯腈丁二烯苯乙烯聚合物。

4. 发明申请

WO1987001286A1 MEDICINAL COMPOSITION 审中-公开
标题翻译：药物组合物
公开(公告)号：WO1987001286A1
公开(公告)日：1987-03-12
申请号：PCT/GB1986000507
申请日：1986-08-27
申请人： RESEARCH CORPORATION LIMITED , GILCHRIST, Thomas , MANSON, William
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： A61K37/18
CPC分类号： A61K38/018 , A61M1/1654 , A61M1/287 , Y10S530/832 , Y10S530/833
摘要： A medicinal composition, particularly but not exclusively for use in fluids for medical dialysis, contains, as an agent for maintaining the osmolality of the fluid, a protein hydrolysate resulting from the action of a proteolytic enzyme on the sodium caseinate fraction of milk protein. The enzyme is preferably trypsin but other proteolytic enzymes and enzyme mixtures may be used, examples being chymotrypsin, pancreatin and pronase. The method of production involves treating the sodium caseinate in aqueous medium with the enzyme at the appropriate pH and temperature for optimum enzyme activity. The product of the enzymic hydrolysis, after filtration through a bacterial filter, adjustment of the osmolality to an appropriate level of around 300 mOsm/Kg and the pH to physiological level of about 6.6 and addition of physiological salt levels, constitutes the final product.
摘要翻译：特别但不排他地用于医疗透析用流体的药物组合物含有由蛋白水解酶对乳蛋白的酪蛋白酸钠级分作用而产生的蛋白质水解物作为维持流体渗透压的试剂。该酶优选为胰蛋白酶，但也可使用其他蛋白水解酶和酶混合物，例如胰凝乳蛋白酶，胰酶和链霉蛋白酶。生产方法包括在适当的pH和温度下用酶处理含水介质中的酪蛋白酸钠，以获得最佳的酶活性。酶水解的产物通过细菌过滤器过滤后，将重量克分子渗透压浓度调节至约300mOsm / Kg的适当水平，pH至6.6的生理水平并加入生理盐水平构成最终产物。

5. 发明申请

WO1989000696A1 ANTENATAL SCREENING FOR DOWN'S SYNDROME 审中-公开
标题翻译：对下来的综合征的ANTNATAL筛选
公开(公告)号：WO1989000696A1
公开(公告)日：1989-01-26
申请号：PCT/GB1988000557
申请日：1988-07-11
申请人： RESEARCH CORPORATION LIMITED , WALD, Nicholas, John , CUCKLE, Howard, Stephen , CANICK, Jacob, Abraham , HADDOW, James, Edward
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： G01N33/74
CPC分类号： G01N33/689 , G01N33/743 , G01N33/76 , G01N2800/387
摘要： An antenatal screening test for risk of Down's Syndrome in a foetus, which is carried out on a maternal blood sample before the beginning of the third trimester of pregnancy, comprises assaying the sample for a metabolite of feto-placental activity which is affected by the presence of Down's Syndrome, and which may be selected from unconjugated oestriol; progesterone; 16-alpha-hydroxy-dehydroepiandrosterone sulphate (16-alpha-hydroxy-DHEAS); and, dehydroepiandrosterone sulphate (DHEAS). The method may also include an additional assay for alpha-fetoprotein and/or human chorionic gonadotrophin.
摘要翻译：在妊娠前三孕期开始的孕妇血液样品中进行胎儿唐氏综合征风险的产前筛查试验包括测定样品中胎盘活性的代谢物，其受到存在的影响的唐氏综合征，其可以选自未缀合的雌三醇; 孕激素; 16-α-羟基 - 脱氢表雄酮硫酸酯（16-α-羟基-DEEAS）; 和脱氢表雄酮硫酸盐（DHEAS）。该方法还可以包括甲胎蛋白和/或人绒毛膜促性腺激素的另外的测定。

6. 发明申请

WO1988007047A1 INOSITOL PHOSPHATE ANALOGUES 审中-公开
标题翻译： INOSITOL磷酸酯类似物
公开(公告)号：WO1988007047A1
公开(公告)日：1988-09-22
申请号：PCT/GB1988000186
申请日：1988-03-10
申请人： RESEARCH CORPORATION LIMITED , POTTER, Barry, Victor, Lloyd
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07F09/177
CPC分类号： C07F9/177 , Y02P20/55
摘要： Novel inositol phosphorothioates have the general formula (I) C6H6(OH)n[(OPO2S) ]m[(OPO2O) ]6-m-n in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6. They may be prepared by a method comprising reacting an inositol derivative having the general formula (II) C6H6(OB)n[OP(OCH2CH2CN)2]6-n in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur, which may or may not be radioactive, in a solvent therefor, and removing the hydroxyl-protecting groups from the product of the reaction. Phosphate esters may be prepared by oxidising the compound of formula (II) with an organic peroxide.
摘要翻译：新的肌醇硫代磷酸酯具有通式（I）C 6 H 6（OH）n [（OPO 2 S）2 - ] m [（OPO 2 O）2 - ]] 6-nn，其中n为0或1至5的整数， m为1〜6的整数。它们可以通过包括使具有通式（II）的C6H6（OB）n [OP（OCH2CH2CN）2] 6-n的肌醇衍生物与其中n为0或 B为1〜5的整数，B表示羟基保护基，在其溶剂中可含或不具有放射性的元素硫溶液，并从反应产物中除去羟基保护基。磷酸酯可以通过用有机过氧化物氧化式（II）的化合物来制备。

7. 发明申请

WO1987005885A1 PLANT PACKAGE 审中-公开
标题翻译：工厂包装
公开(公告)号：WO1987005885A1
公开(公告)日：1987-10-08
申请号：PCT/GB1987000218
申请日：1987-04-01
申请人： RESEARCH CORPORATION LIMITED , CASSELLS, Alan, Condon
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： B65D85/52
CPC分类号： B65D85/52 , B65D81/263 , B65D2565/388
摘要： A package (1) for the production and/or storage of plants, comprising a sealed container (2) for the plants in which at least a portion of the container is a membrane assembly of at least two selectively permeable membrane layers, an innermost membrane (5) having relatively high permeability to both gases and water vapour and an outermost membrane (6) having relatively high permeability to gases but being substantially impermeable to water vapour, said outer membrane layer (6) being strippable from the package leaving the innermost membrane (5) intact.

8. 发明申请

WO1989003696A1 BLOOD PURIFICATION APPARATUS 审中-公开
标题翻译：血液净化装置
公开(公告)号：WO1989003696A1
公开(公告)日：1989-05-05
申请号：PCT/GB1988000920
申请日：1988-10-21
申请人： RESEARCH CORPORATION LIMITED , GREENWOOD, Roger, Newton , ALDRIDGE, Colin , TATTERSALL, James, Erskine , BARRETT, Rodney, Valentine
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： A61M01/30
CPC分类号： A61M1/30 , A61M1/1006 , A61M1/1037 , A61M1/1063 , A61M1/1698 , A61M1/303 , A61M1/308 , A61M1/3434 , A61M1/3437 , A61M1/3604 , A61M1/3679 , A61M5/1486
摘要： Blood purification apparatus comprises a dead-end system in which blood from the patient is allowed to flow through one or more purification modules (4), such as a dialyser, a haemofilter, a haemoperfusion column and an oxygenator, into a resiliently walled reservoir (6), which is conveniently a standard blood bag. The direction of flow of the blood is then reversed by exertion of sufficient pressure on the bag (6) to push the blood back through the purification module (4) to the patient's circulation. Thus, since the reservoir is of variable capacity, being of resilient material for example, the capacity of the apparatus remains equal to the volume of extra-corporeal blood.
摘要翻译：血液净化装置包括死端系统，其中允许来自患者的血液通过一个或多个净化模块（例如透析器，血液滤过器，血液灌注柱和充氧器）流入弹性壁储存器，这是方便的一个标准血袋。然后通过在袋上施加足够的压力来逆转血液的流动方向，以将血液通过净化模块推回患者的循环。因此，由于储存器具有可用容量，例如具有弹性材料，装置的容量保持等于体外血液的体积。

9. 发明申请

WO1988009321A1 SUBSTITUTED PHENONE 审中-公开
标题翻译：取代的PHENONE
公开(公告)号：WO1988009321A1
公开(公告)日：1988-12-01
申请号：PCT/GB1988000406
申请日：1988-05-23
申请人： RESEARCH CORPORATION LIMITED , MORRIS, Howard, Redfern , KAY, Robert, Roger , MASENTO, Mark, Steven , TAYLOR, Graham, Walter
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07C49/84
CPC分类号： C07C49/84 , C07C45/00 , C07C45/42 , C07C45/54 , C07C49/825 , C07C49/83 , C07C49/835
摘要： A compound which has the biological action of inducing cell differentiation has general chemical formula (I), in which R1 is a straight or branched chain or cyclic alkyl or alkenyl group; R2 is an alkoxy or hydroxy group; R3 is a hydrogen or halogen atom; and, R4 is a halogen atom. Preferred values for the groups are R1 = C3 to C8 alkyl; R2 = methoxy; and, either or both of R3 and R4 = chlorine. The compounds: 1) 2,6-dihydroxy-3,5-dichloro-4-methoxy valerophenone; 2) 2,6-dihydroxy-3,5-dichloro-4-methoxy butyrophenone; and, 3) 2,6-dihydroxy-3-chloro-4-methoxy valerophenone are of particular interest.
摘要翻译：具有诱导细胞分化的生物学作用的化合物具有通式（I），其中R 1为直链或支链或环状烷基或链烯基; R2是烷氧基或羟基; R3是氢或卤原子; R4为卤素原子。基团的优选值为R 1 = C 3至C 8烷基; R2 =甲氧基; 并且R 3和R 4之一或两者均为氯。化合物：1）2,6-二羟基-3,5-二氯-4-甲氧基缬草酮; 2）2,6-二羟基-3,5-二氯-4-甲氧基丁酰苯; 和，3）2,6-二羟基-3-氯-4-甲氧基缬草酮是特别感兴趣的。

10. 发明申请

WO1988001254A1 MODIFICATION OF ZEOLITES 审中-公开
标题翻译： ZEOLITES的修改
公开(公告)号：WO1988001254A1
公开(公告)日：1988-02-25
申请号：PCT/GB1987000591
申请日：1987-08-21
申请人： RESEARCH CORPORATION LIMITED , REES, Lovat, Victor, Charles , LEE, Edward, Fook, Tin
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C01B33/28
CPC分类号： C01B33/2884 , B01J29/04 , B01J29/084 , B01J2229/16 , B01J2229/183 , B01J2229/32 , B01J2229/34 , C01B35/1009 , C01B39/026 , C10G11/05
摘要： A method for the modification of the framework structure of a zeolite comprises treating the zeolite with a solution in an organic solvent of a compound of an element capable of structural remplacement of aluminium in the framework, the aluminium-replacing element being selected from, for example, boron, tin, silicon, titanium, germanium, gallium, phosphorus, beryllium and magnesium preferably in the form of their halides or organometallic compounds. Typical compounds are BCl3, BBr3, SnCl4, SnBr4, SnI4, SiCl4, SiI4, TiCl4, GeCl4, GaCl4, PCl5, BeCl2, MgCl2 and beryllium diphenyl. In a preferred embodiment the zeolite is reacted with silicon tetrachloride in carbon tetrachloride under reflux. However, the reaction time can be reduced by utilizing a solvent which has a molecular size which prevents it entering the channels of the zeolite, one such solvent being tetraethoxysilane.
摘要翻译：用于改性沸石的骨架结构的方法包括用在框架中能够结构地重新置换铝的元素的化合物的有机溶剂中的溶液处理沸石，铝替代元件例如选自，硼，锡，硅，钛，锗，镓，磷，铍和镁以其卤化物或有机金属化合物的形式。典型的化合物是BCl3，BBr3，SnCl4，SnBr4，SnI4，SiCl4，SiI4，TiCl4，GeCl4，GaCl4，PCl5，BeCl2，MgCl2和铍二苯。在优选的实施方案中，沸石在四氯化碳中在回流下与四氯化硅反应。然而，可以通过利用具有防止其进入沸石通道的分子尺寸的溶剂来降低反应时间，一种这样的溶剂是四乙氧基硅烷。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式